secwatch.observer — SEC 8-K summary
======================================

Issuer:     Pear Therapeutics, Inc. (—)
CIK:        0001835567
Form:       8-K
Filed at:   2022-11-14T23:59:59+00:00
Accession:  0001835567-22-000073
Event type: earnings
Sentiment:  neutral
Materiality: 0.75
Item codes: 2.02, 2.05, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Pear Therapeutics Q3 revenue $4.1M, +24% QoQ; cuts 22% workforce
----------------------------------------------------------------

- Revenue $4.1M in Q3 2022, up 24% from Q2 2022 and 211% vs Q3 2021.
- Workforce reduced by ~59 employees (22% of total); expects $2.6M cash severance costs in Q4 2022.
- Annual cash cost savings from workforce reduction estimated at $10.7M.
- 2022 revenue guidance reaffirmed at $14-16M; 2023 revenue guidance set at $27-37M.
- Key operating metrics: prescriptions 11,400+, fulfillment rate 60%, payment rate 49%, ASP $1,345.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1835567/000183556722000073/0001835567-22-000073-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1835567/000183556722000073/pear-20221114.htm
  HTML page:      https://secwatch.observer/filing/0001835567-22-000073

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer